HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Consumer Reports Issues 2019 Sunscreen Recommendations; All Contain Oxybenzone

Executive Summary

While acknowledging concerns about oxybenzone, Consumer Reports maintains the importance of sunscreen to help prevent skin cancer and says oxybenzone-containing offerings continue to test best when it comes to broad-spectrum protection and minimal SPF “variation.”

You may also be interested in...



Cosmetics Market In 2019: CBD, Microplastic And US Sunscreen Uncertainty Among Year’s Biggest Issues

The opportunity represented by cannabidiol, and the uncertain future for commonly used sunscreen active ingredients in the US and microplastic in the EU, were issues of high interest among cosmetics industry stakeholders in 2019.

EWG Casts FDA’s Proposed Sunscreen Rule As Validation Of Longstanding Concerns

The Environmental Working Group has long favored mineral over chemical sunscreens in its annual ratings and buying guide, with particular concerns about oxybenzone, one of 12 active ingredients that FDA says need additional safety data to support GRASE determinations.

FDA MUsT Shows Sunscreen Ingredient Absorption ‘Not Just A Theoretical Concern’

In FDA’s maximal usage trial published May 6 in JAMA, oxybenzone, octocrylene, avobenzone and ecamsule all absorbed into subjects’ bloodstreams at levels that raise systemic safety questions. The active ingredients are among 12 that FDA identified in a February proposed rule as currently lacking data to support continued GRASE status.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148794

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel